ES2481791T3 - Compuestos novedosos y uso terapéutico para la inhibición de proteína cinasa - Google Patents
Compuestos novedosos y uso terapéutico para la inhibición de proteína cinasa Download PDFInfo
- Publication number
- ES2481791T3 ES2481791T3 ES10817865.8T ES10817865T ES2481791T3 ES 2481791 T3 ES2481791 T3 ES 2481791T3 ES 10817865 T ES10817865 T ES 10817865T ES 2481791 T3 ES2481791 T3 ES 2481791T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- heteroaromatic
- unsubstituted
- protein kinase
- novel compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula I: en la que Y >= NH, R1 >= seleccionado de los siguientes grupos: en el que X >= CH2, NH, S u O, R8 >= -H, -NH2, -OH, -N(R4, R5), -C(R4, R5)1-7NR6R7, -C(R4R5)1-7OR6, o N(R4)NR5R6, en el que R4, R5, R6, R7 >= H, alquilos C1-C6, cicloalquilos C3-C8, con o sin heteroátomos nucleares, tales como O, S, y N, arilos (aromáticos sustituidos o bien insustituidos), o heteroaromáticos (heteroaromáticos sustituidos o bien insustituidos), R9, R10, R11, R12, y R13 >= H, alquilos C1-C6, cicloalquilos C3-C8 con o sin heteroátomos nucleares tales como O, S o N, arilos (aromáticos sustituidos o bien insustituidos), o heteroaromáticos (heteroaromáticos sustituidos o bien insustituidos), R2 se selecciona de un grupo que consiste en H, OH, NH2, OR14, NR14R15, alquilo, arilo, heteroarilo, cicloalquilo, arilalquilo, heterociclilo, heterociclilalquilo, alquenilo, y alquinilo, en el que , R15 >= H, alquilos C1-C6, cicloalquilos C1-C8 con o sin heteroátomos nucleares tales como O, S, N, arilos (aromáticos sustituidos o bien insustituidos), o heteroaromáticos (heteroaromáticos sustituidos o bien insustituidos), y R3 se selecciona de un grupo que consiste en H, alquilo, arilo, heteroarilo, cicloalquilo, arilalquilo, heterociclilo, heterociclilalquilo, alquenilo, y alquinilo.
Description
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24354909P | 2009-09-18 | 2009-09-18 | |
US243549P | 2009-09-18 | ||
PCT/US2010/049199 WO2011035077A1 (en) | 2009-09-18 | 2010-09-17 | Novel compounds and therapeutic use thereof for protein kinase inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2481791T3 true ES2481791T3 (es) | 2014-07-31 |
Family
ID=43759014
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10817865.8T Active ES2481791T3 (es) | 2009-09-18 | 2010-09-17 | Compuestos novedosos y uso terapéutico para la inhibición de proteína cinasa |
ES14164666.1T Active ES2587509T3 (es) | 2009-09-18 | 2010-09-17 | Derivados de tieno[2,3-d]piridazina y uso terapéutico de los mismos para la inhibición de proteína cinasa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14164666.1T Active ES2587509T3 (es) | 2009-09-18 | 2010-09-17 | Derivados de tieno[2,3-d]piridazina y uso terapéutico de los mismos para la inhibición de proteína cinasa |
Country Status (14)
Country | Link |
---|---|
US (2) | US8815863B2 (es) |
EP (2) | EP2826780B1 (es) |
JP (1) | JP6155026B2 (es) |
CN (2) | CN102711475B (es) |
AU (2) | AU2010295492B2 (es) |
BR (1) | BR112012006062A2 (es) |
CA (1) | CA2774367C (es) |
ES (2) | ES2481791T3 (es) |
HK (1) | HK1170908A1 (es) |
IN (1) | IN2012DN03127A (es) |
MX (1) | MX2012003286A (es) |
NZ (1) | NZ599453A (es) |
RU (1) | RU2012109220A (es) |
WO (1) | WO2011035077A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2774367C (en) * | 2009-09-18 | 2018-07-10 | Zhanggui Wu | Compounds and therapeutic use thereof for protein kinase inhibition |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
WO2021141980A1 (en) * | 2020-01-07 | 2021-07-15 | Fan Wu | Combination cancer therapy using chk inhibitor |
JP7407298B2 (ja) * | 2020-03-04 | 2023-12-28 | ファロス・アイバイオ・カンパニー・リミテッド | 2,3,5-置換されたチオフェン化合物の卵巣癌の予防、改善または治療用途 |
CN115605484A (zh) * | 2020-04-17 | 2023-01-13 | 浙江医药股份有限公司新昌制药厂(Cn) | 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用 |
CN116332960A (zh) * | 2021-12-23 | 2023-06-27 | 上海优理惠生医药有限公司 | 一种哒嗪类化合物、其药物组合物及应用 |
CN117263950A (zh) * | 2022-06-13 | 2023-12-22 | 上海优理惠生医药有限公司 | 一种哒嗪类化合物、其药物组合物及应用 |
CN117003736B (zh) * | 2023-10-07 | 2023-12-15 | 天津匠新致成科技有限公司 | 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029241A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
WO2003028731A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
AU2003270701B2 (en) * | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
CN1950378A (zh) * | 2004-05-04 | 2007-04-18 | 霍夫曼-拉罗奇有限公司 | 作为ikk抑制剂的噻吩并哒嗪类化合物 |
EP1745050A1 (en) * | 2004-05-04 | 2007-01-24 | F.Hoffmann-La Roche Ag | Thienopyridines as ikk inhibitors |
MX2007012448A (es) * | 2005-04-06 | 2007-10-19 | Astrazeneca Ab | Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak. |
CN101189243A (zh) | 2005-04-06 | 2008-05-28 | 阿斯利康(瑞典)有限公司 | 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用 |
CA2649543A1 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
US8241918B2 (en) | 2006-07-03 | 2012-08-14 | Koninklijke Philips Electronics N.A. | Beverage dispensing device with freshness indicator |
CN101481380B (zh) | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
CA2774367C (en) * | 2009-09-18 | 2018-07-10 | Zhanggui Wu | Compounds and therapeutic use thereof for protein kinase inhibition |
-
2010
- 2010-09-17 CA CA2774367A patent/CA2774367C/en active Active
- 2010-09-17 WO PCT/US2010/049199 patent/WO2011035077A1/en active Application Filing
- 2010-09-17 ES ES10817865.8T patent/ES2481791T3/es active Active
- 2010-09-17 BR BR112012006062A patent/BR112012006062A2/pt not_active Application Discontinuation
- 2010-09-17 US US13/496,494 patent/US8815863B2/en active Active
- 2010-09-17 AU AU2010295492A patent/AU2010295492B2/en active Active
- 2010-09-17 RU RU2012109220/04A patent/RU2012109220A/ru not_active Application Discontinuation
- 2010-09-17 JP JP2012529908A patent/JP6155026B2/ja active Active
- 2010-09-17 CN CN201080042057.8A patent/CN102711475B/zh active Active
- 2010-09-17 CN CN201410809035.XA patent/CN104628741A/zh active Pending
- 2010-09-17 NZ NZ599453A patent/NZ599453A/en unknown
- 2010-09-17 EP EP14164666.1A patent/EP2826780B1/en active Active
- 2010-09-17 MX MX2012003286A patent/MX2012003286A/es active IP Right Grant
- 2010-09-17 ES ES14164666.1T patent/ES2587509T3/es active Active
- 2010-09-17 EP EP10817865.8A patent/EP2477496B1/en active Active
-
2012
- 2012-04-11 IN IN3127DEN2012 patent/IN2012DN03127A/en unknown
- 2012-11-21 HK HK12111873.5A patent/HK1170908A1/xx unknown
-
2014
- 2014-07-17 US US14/333,529 patent/US9487539B2/en active Active
-
2016
- 2016-07-12 AU AU2016204867A patent/AU2016204867B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2477496B1 (en) | 2014-04-16 |
AU2010295492B2 (en) | 2016-05-05 |
JP6155026B2 (ja) | 2017-06-28 |
EP2826780A1 (en) | 2015-01-21 |
WO2011035077A1 (en) | 2011-03-24 |
ES2587509T3 (es) | 2016-10-25 |
CN104628741A (zh) | 2015-05-20 |
IN2012DN03127A (es) | 2015-09-18 |
BR112012006062A2 (pt) | 2015-09-08 |
CN102711475B (zh) | 2015-01-28 |
US8815863B2 (en) | 2014-08-26 |
US20120232082A1 (en) | 2012-09-13 |
JP2013505254A (ja) | 2013-02-14 |
AU2016204867B2 (en) | 2017-02-16 |
US9487539B2 (en) | 2016-11-08 |
MX2012003286A (es) | 2012-06-19 |
AU2016204867A1 (en) | 2016-07-28 |
CA2774367C (en) | 2018-07-10 |
NZ599453A (en) | 2014-03-28 |
US20150072987A1 (en) | 2015-03-12 |
EP2477496A1 (en) | 2012-07-25 |
RU2012109220A (ru) | 2013-10-27 |
EP2826780B1 (en) | 2016-06-01 |
AU2010295492A1 (en) | 2012-05-03 |
CN102711475A (zh) | 2012-10-03 |
EP2477496A4 (en) | 2013-02-27 |
CA2774367A1 (en) | 2011-03-24 |
HK1170908A1 (en) | 2013-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2481791T3 (es) | Compuestos novedosos y uso terapéutico para la inhibición de proteína cinasa | |
ES2486267T3 (es) | 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas | |
ES2640049T3 (es) | Derivados de 3,6-dihidropirimidina 2,4,5,6-sustituidos como inhibidores de la polimerasa del virus de la hepatitis B (VHB) para el tratamiento de, por ejemplo, la hepatitis crónica | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
ES2526338T3 (es) | Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad | |
AR073136A1 (es) | Compuestos de pirrol | |
PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR055620A1 (es) | Derivados de cicloalcano-carboxamidas | |
ES2552462T3 (es) | Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo | |
PE20091236A1 (es) | Derivados de pirimidina como immunomoduladores de tlr7 | |
AR064459A1 (es) | Derivados de sulfonamida | |
ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
AR066421A1 (es) | Compuestos derivados de piridona | |
ES2578302T3 (es) | Compuestos de 5,6-dihidro-1H-piridin-2-ona | |
CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
ES2523302T3 (es) | Colorantes azoicos | |
AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
CO5660292A2 (es) | Pirimidinas 2-sustituidas |